Information  X 
Enter a valid email address

Sensyne Health PLC (SENS)

  Print   

Friday 30 October, 2020

Sensyne Health PLC

Result of AGM

RNS Number : 8248D
Sensyne Health PLC
30 October 2020
 

Result of Annual General Meeting

 

 

Oxford, U.K. 30 October 2020:   Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the UK Clinical AI company, announces that at its virtual Annual General Meeting ('AGM') held today at 2pm GMT, all resolutions were duly passed. Results are set out below and the full text of the resolutions considered at the AGM is contained in the notice of AGM published on 06 October 2020 which is available on Sensyne's website.

 

Commenting at the event, Sir Bruce Keogh, Non-Executive Chairman of Sensyne Health , said:

 

"Sensyne is in a strong position to apply its technology and expertise to help the life sciences and healthcare industries manage the short term challenges associated with coronavirus. Our software suite is being used to conduct clinical trials, monitor personal symptoms and disease progression and deliver remote patient care. In the long term, we are building a business that contributes to, and directly connects into, an increasingly digitised healthcare future. 

 

Most importantly we embody a better way to build technology companies - a way that recognises, respects and addresses the public, professional and institutional sensitivities related to ownership and privacy of highly personal healthcare data ."

 

For information, full details of the votes received were as follows and all information will shortly be posted on the Company's website ( www.sensynehealth.com ):

 

 

Res No.

Votes For

%

Votes Against

%

Votes Total

% I.S.C.

Votes Withheld

01

76,467,429

100.00%

0

0.00%

76,467,429

59.47

0

02

74,777,158

97.79%

1,690,271

2.21%

76,467,429

59.47

0

03

75,488,059

98.72%

976,870

1.28%

76,464,929

59.47

2,500

04

76,434,779

99.96%

32,650

0.04%

76,467,429

59.47

0

05

76,467,429

100.00%

0

0.00%

76,467,429

59.47

0

06

74,924,805

97.98%

1,542,624

2.02%

76,467,429

59.47

0

07

76,467,429

100.00%

0

0.00%

76,467,429

59.47

0

08

76,464,511

100.00%

2,918

0.00%

76,467,429

59.47

0

09

76,465,159

100.00%

2,270

0.00%

76,467,429

59.47

0

10

76,426,569

99.95%

36,860

0.05%

76,463,429

59.47

4,000

11

76,408,258

99.96%

29,171

0.04%

76,437,429

59.45

30,000

12

76,408,758

99.97%

26,171

0.03%

76,434,929

59.45

32,500

13

75,423,313

98.63%

1,044,116

1.37%

76,467,429

59.47

0

At the AGM the following statement was also read out by Sir Bruce Keogh, Non-Executive Chairman of Sensyne Health:

"During the course of the financial year, Lorimer Headley left the Board. He was an instrumental part of the successful IPO of Sensyne Health plc and subsequent commercial agreements, and prior to that provided a valuable contribution to the development of Drayson Technologies. On behalf of the Board, we would like to thank Mr Headley for his significant contribution to Sensyne."

-ENDS-

 

For more information please contact:

Sensyne Health ( www.sensynehealth.com )

+44 (0) 330 058 1845

Lord (Paul) Drayson PhD FREng, Chief Executive Officer


Michael Norris, Interim Chief Financial Officer


 

Peel Hunt LLP (Nominated Adviser and Joint Broker)

 

+ 44 (0) 20 7418 8900

Dr Christopher Golden


James Steel


Oliver Jackson


Liberum (Joint Broker)

+ 44 (0) 20 3100 2000

Bidhi Bhoma


Euan Brown


Consilium Strategic Communications

+44 (0) 77 0286 8207

Mary-Jane Elliott


Sukaina Virji


Melissa Gardiner


CSCS [email protected]


 

 

 

About Sensyne Health  

 

Sensyne Health plc is a clinical AI company that works in partnership with the NHS to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

 

For more information, please visit: www.sensynehealth.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGURONRRRUROAA

a d v e r t i s e m e n t